Main Menu

Foamix Pharmaceuticals, Inc.

(NASDAQ GS: FOMX)

Summary

Attention investors who purchased shares of Foamix Pharmaceuticals, Inc. before November 11, 2019:

Rigrodsky & Long is investigating potential claims against the board of directors of Foamix Pharmaceuticals Ltd. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with Menlo Therapeutics Inc.  

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Foamix Pharmaceuticals Ltd. (“Foamix” or the “Company”) (NASDAQ GS: FOMX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Menlo Therapeutics Inc. (“Menlo”) (NASDAQ GS: MNLO).  Under the terms of the agreement, shareholders of Foamix will receive 0.5924 of a share of Menlo common stock and a contingent stock right (“CSR”) for each share of Foamix they own.

If you own common stock of Foamix and purchased any shares before November 11, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page